We serve Chemical Name:3-Bromo-5-chloropyridine CAS:73583-39-8 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
Chemical Name:3-Bromo-5-chloropyridine
CAS.NO:73583-39-8
Synonyms:Pyridine, 3-bromo-5-chloro-;3-Bromo-5-chloropyridine;3-Chloro-5-bromopyridine;MFCD04114221
Molecular Formula:C5H3BrClN
Molecular Weight:192.441
HS Code:2933399090
Physical and Chemical Properties:
Melting point:80-82°C
Boiling point:194.7±20.0 °C at 760 mmHg
Density:1.7±0.1 g/cm3
Index of Refraction:1.581
PSA:12.89000
Exact Mass:190.913727
LogP:2.54
Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:UN 2811 6.1/PG 3
Packing Group:III
Contact us for information like Pyridine, 3-bromo-5-chloro- chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,MFCD04114221 physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,3-Chloro-5-bromopyridine Use and application,MFCD04114221 technical grade,usp/ep/jp grade.
Related News: Though the program obtained priority review from FDA back in November, analysts expressed skepticism in July 2020 after it failed to prove superior to the companies’ other drug Lumizyme in improving respiratory function in a Phase III trial. 2-carboxy-4-(ethylthio)butanoic acid manufacturers In Massachusetts, where the bulk of Takeda’s U.S. operations are based since the Shire buyout, the Japanese pharma has been swiftly ramping up its cell therapy ambitions. In September, the company cut the ribbon on a new 24,000-square-foot R&D manufacturing center in Boston, which it said at the time would handle clinical development for three ongoing pipeline programs and two other prospects pegged to enter clinical development by the end of 2021. rel-(1R,3S)-N-(3,5-bis(trifluoromethyl)benzyl)-1-(2-hydroxypropan-2-yl)-3-((tetrahydro-2H-pyran-4-yl)amino)cyclopentane-1-carboxamide suppliers In Massachusetts, where the bulk of Takeda’s U.S. operations are based since the Shire buyout, the Japanese pharma has been swiftly ramping up its cell therapy ambitions. In September, the company cut the ribbon on a new 24,000-square-foot R&D manufacturing center in Boston, which it said at the time would handle clinical development for three ongoing pipeline programs and two other prospects pegged to enter clinical development by the end of 2021. 4,4′-((2-(tert-butyl)anthracene-9,10-diyl)bis(ethyne-2,1-diyl))bis(2,5-bis(hexyloxy)benzaldehyde) vendor & factory Though the program obtained priority review from FDA back in November, analysts expressed skepticism in July 2020 after it failed to prove superior to the companies’ other drug Lumizyme in improving respiratory function in a Phase III trial.,Expedite biocatalysis development by partnering with an API CDMO
